Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.28 Insider Own9.14% Shs Outstand3.11M Perf Week-43.02%
Market Cap3.05M Forward P/E- EPS next Y-2.52 Insider Trans0.00% Shs Float2.83M Perf Month-40.61%
Income-8.43M PEG- EPS next Q-0.77 Inst Own2.04% Short Float12.17% Perf Quarter-54.21%
Sales0.09M P/S33.86 EPS this Y89.27% Inst Trans7.93% Short Ratio10.28 Perf Half Y-37.18%
Book/sh0.98 P/B1.00 EPS next Y-29.45% ROA-87.68% Short Interest0.34M Perf Year-92.93%
Cash/sh1.22 P/C0.80 EPS next 5Y- ROE-200.09% 52W Range0.90 - 18.26 Perf YTD-43.68%
Dividend Est.- P/FCF- EPS past 5Y74.20% ROI-267.96% 52W High-94.63% Beta0.52
Dividend TTM- Quick Ratio1.89 Sales past 5Y-37.47% Gross Margin14.90% 52W Low9.14% ATR (14)0.17
Dividend Ex-Date- Current Ratio1.89 EPS Y/Y TTM94.80% Oper. Margin-13472.18% RSI (14)25.53 Volatility12.70% 8.90%
Employees12 Debt/Eq0.06 Sales Y/Y TTM-53.29% Profit Margin-9087.11% Recom1.00 Target Price11.50
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q101.05% Payout- Rel Volume0.00 Prev Close0.98
Sales Surprise-100.00% EPS Surprise110.00% Sales Q/Q-100.00% EarningsMay 14 AMC Avg Volume33.50K Price0.98
SMA20-38.59% SMA50-42.95% SMA200-47.45% Trades Volume0 Change0.00%
Jun-20-24 08:30AM
Jun-13-24 08:00AM
May-28-24 08:00AM
May-22-24 07:00AM
May-20-24 09:15AM
09:53AM Loading…
May-15-24 09:53AM
May-14-24 04:15PM
May-06-24 07:00AM
May-03-24 09:00AM
Mar-19-24 07:30AM
Mar-11-24 07:30AM
Feb-29-24 04:05PM
Feb-14-24 07:30AM
Dec-21-23 08:00AM
Dec-14-23 04:15PM
07:30AM Loading…
Oct-31-23 07:30AM
Oct-25-23 07:30AM
Oct-17-23 08:00AM
Sep-20-23 07:30AM
Sep-19-23 08:30AM
Aug-31-23 10:55AM
Aug-16-23 07:30AM
Aug-14-23 08:00AM
Jul-31-23 09:00AM
Jun-28-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
May-10-23 07:30AM
Apr-18-23 04:01PM
Apr-17-23 08:00AM
04:31PM Loading…
Mar-14-23 04:31PM
Feb-13-23 08:00AM
Feb-08-23 08:00AM
Feb-01-23 08:00AM
Jan-19-23 08:00AM
Jan-09-23 08:00AM
Dec-15-22 04:05PM
Nov-02-22 08:00AM
Nov-01-22 04:05PM
Oct-31-22 07:30AM
Oct-04-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 08:00AM
Sep-16-22 08:30AM
Aug-15-22 04:05PM
Jul-22-22 07:00AM
Jul-21-22 07:30AM
Jun-09-22 07:00AM
Jun-02-22 09:25AM
May-10-22 08:15AM
Apr-13-22 07:00AM
Apr-08-22 01:05PM
Mar-16-22 07:00AM
Feb-09-22 06:30AM
Feb-08-22 07:00AM
Dec-20-21 12:58PM
Dec-17-21 06:30AM
Aug-30-21 04:01PM
Aug-19-21 09:35PM
Aug-16-21 06:30AM
Jun-14-21 07:45AM
Jun-08-21 04:30PM
May-17-21 07:00AM
May-10-21 06:30AM
May-03-21 06:00AM
Mar-29-21 04:30PM
Mar-22-21 07:00AM
Feb-16-21 08:10AM
Feb-03-21 06:30AM
Feb-01-21 06:30AM
Jan-25-21 06:30AM
Dec-17-20 06:30AM
Nov-30-20 08:30AM
Sep-01-20 08:30AM
Aug-25-20 07:30AM
Aug-24-20 07:37AM
Aug-14-20 07:30AM
Aug-04-20 07:35AM
Jul-20-20 07:30AM
Jul-15-20 07:30AM
May-18-20 07:30AM
Apr-06-20 07:30AM
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.